Thromboxane A2 mediates increased pulmonary microvascular permeability after intestinal reperfusion

Area of Science:

• Physiology
• Pulmonary Medicine
• Vascular Biology

Background:

• Intestinal ischemia-reperfusion (IR) injury is a significant clinical concern.
• Pulmonary complications, including edema and vasoconstriction, can arise from IR.
• The role of thromboxane A2 (TxA2) in mediating these pulmonary effects requires elucidation.

Purpose of the Study:

• To investigate the hypothesis that IR-induced pulmonary thromboxane A2 (TxA2) release elevates microvascular permeability and causes vasoconstriction.
• To determine the contribution of TxA2 to IR-induced pulmonary edema.

Main Methods:

• Sprague-Dawley rats underwent 120 minutes of intestinal ischemia followed by 60 minutes of reperfusion (IR) or sham operation.
• Ex vivo lung perfusion was utilized to measure pulmonary microvascular filtration coefficient (Kf) and pressures (Ppa, Ppv, Ppc) to assess vascular resistance (Rt).
• TxA2 synthase inhibitor (imidazole) and TxA2-receptor antagonist (SQ-29,548) were administered to assess their effects on IR-induced changes.

Main Results:

• IR significantly increased lung microvascular permeability (Kf) and vascular resistance (Rt) compared to sham controls.
• Pulmonary capillary pressure (Pc) was elevated in IR lungs.
• Imidazole and SQ-29,548 partially reversed the IR-induced increases in Kf and Rt, with imidazole showing a slight reduction in Pc at higher doses.

Conclusions:

• Intestinal reperfusion injury leads to increased pulmonary microvascular permeability and hydrostatic pressure, contributing to pulmonary edema.
• Thromboxane A2 (TxA2) plays a significant role in mediating these IR-induced pulmonary vascular changes.
• Inhibition of TxA2 synthesis or receptor blockade may offer therapeutic benefits in mitigating IR-induced pulmonary complications.